Salute e Benessere

QL Biopharm Presented Results from Phase 1c Clinical Study on its Novel…

The presentation titled 'ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: A randomized, placebo-controlled, multiple ascending dose phase 1c study' highlighted recent findings on QL Biopharm's lead drug candidate ZT002 - a novel ultra long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) in development for obesity with monthly subcutaneous administration. The presentation titled'ZT002, a novel ultra long-acting GLP-1 receptor agonist in...
PR Newswire
12/09/2024

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted…

ITM gains exclusive global development and commercialization rights to Debiopharm's first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([ 177 Lu]Lu-DPI-4452) and diagnostic imaging agent, Debio 0328 ([ 68 Ga]Ga-DPI-4452) to target Carbonic Anhydrase IX (CA IX) Debiopharm to receive upfront, development and regulatory milestone payments of approximately €300 million, as well as commercial milestones and low double-digit royalties...
Nasdaq GlobeNewswire
12/09/2024

Bavarian Nordic Provides Update on the Mpox Vaccine Supply Situation

COPENHAGEN, Denmark, September 12, 2024– Bavarian Nordic A/S (OMX: BAVA), the vaccine manufacturer of MVA-BN ®, the only approved non-replicating smallpox and mpox vaccine (marketed as JYNNEOS ®, IMVAMUNE ®and IMVANEX ® ) today provided an update of its supply and manufacturing activities in support of the ongoing mpox outbreak.Since the declaration of mpox as a Public Health Emergency of Continental Security (PHECS) by the Africa Centers for Disease Control (CDC) and the subsequent...
Nasdaq GlobeNewswire
12/09/2024

Rising Demand for Microelectronic Medical Implants Propels Market Growth at…

This report provides a comprehensive analysis of the global and regional markets for microelectronic medical implants, utilizing data from 2023, estimates for 2024, and projections for the period from 2024 to 2029. It examines key trends within the market, segmented by product types such as pacemakers, defibrillators, neurostimulators, hearing implants, ocular implants, and others, and applications including cardiology, neurology, audiology, and ophthalmology. The analysis covers regional…
PR Newswire
12/09/2024

SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024

SOPHiA UNITY, the pioneering initiative by SOPHiA GENETICS, harnesses multimodal data and analytics to drive innovation from a global network. The bar for innovation in oncology is increasing as indications become more fragmented, more complex and requiring larger datasets. No single institution can address this challenge alone. SOPHiA GENETICS launched SOPHiA UNITY to meet this challenge, harmonizing high-quality, diverse, multimodal data at scale, leveraging the collective intelligence of…
PR Newswire
12/09/2024

Berlin Heals Strengthens Executive Leadership Team

"Brumfield is a talented medical device executive with a track record of bringing innovative technologies to market. With Berlin Heals' focus on a revolutionary treatment for heart failure, we are thrilled to have someone of Brumfield's cardiac rhythm and heart failure expertise leading the team at Berlin Heals," said Dr.Ulf Berg, Chairman of the Board. "Together with Brumfield's strategic and commercial expertise and Berlin Heals' outstanding team of innovators and…
PR Newswire
12/09/2024

Biocomposites to distribute its NanoBone® product range in the UK

NanoBone's patented technology consists of nanostructured hydroxyapatite embedded in a silica gel matrix, which is suspended in a hydrogel/polymer silica carrier. This formulation provides the fullest support for bone regeneration - providing comparable healing rate to autograft and osteoinductive properties, but without the costs and complications of harvesting. NanoBone is preloaded and ready-to-use in a wide variety of applications to maximise flexibility and efficiency during procedures. ...
PR Newswire
12/09/2024

POLYTECH Expands Portfolio with New Opticon® Plus Breast Implant

Meeting Market Needs with Collaborative Innovation The development of Opticon® Plus is the outcome of a collaborative effort, driven by feedback from leading global plastic surgeons. "Opticon® Plus was designed to offer a new anatomical option that complements our existing range, addressing specific needs that surgeons identified," stated Prof. Dr.Karsten Hemmrich, CEO of POLYTECH. "This implant is a result of direct input from the field, ensuring it meets the demands of both...
PR Newswire
12/09/2024

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on…

Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancersParis, France, and Houston, Texas, September 12, 2024.As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage biotechnology company developing radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT) against unmet...
Nasdaq GlobeNewswire
12/09/2024

Santhera Announces Half-Year 2024 Financial Results and Provides Corporate…

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release.Revenue from contracts with customers of CHF 14.1 million (H1-2023: CHF 3.9 million)Operating result of CHF -17.7 million (H1-2023: CHF -20.3 million) and net result ofCHF -15.3 million (H1-2023: CHF -23.3 million)AGAMREE® (vamorolone) launched in Germany and Austria as first European markets; North...
Nasdaq GlobeNewswire
12/09/2024

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney…

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Primary focus is developing varoglutamstat, a Phase 2 investigational medicine with potential to improve kidney function in patients with kidney diseaseStatistically significant benefit of varoglutamstat on prospectively defined key kidney function endpoint (eGFR 1 ) and significant reduction of pro-inflammatory...
Nasdaq GlobeNewswire
12/09/2024

Genespire appoints Karen Aiach-Pignet as Chief Executive Officer

PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen's appointment bolsters Genespire's position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12 September 2024– Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces the appointment of Karen Aiach-Pignet as Chief Executive Officer following Dr. Julia Berretta, the former CEO, stepping down...
Nasdaq GlobeNewswire
12/09/2024

BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole common share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until September 11, 2026, being the date that is 24 months from the date of issue. Each Unit consists of one common share in the capital of the Company (each, a " Share ") and one whole common share purchase warrant (each, a…
PR Newswire
12/09/2024

Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of…

Key Takeaways from the Nontuberculous Mycobacterial Infection Market Report Key Takeaways from the Nontuberculous Mycobacterial Infection Market Report Discover which therapies are expected to grab the major nontuberculous mycobacterial infection market share @Nontuberculous Mycobacterial Infection Market Report Nontuberculous Mycobacterial Infection Overview Nontuberculous mycobacteria (NTM) infections are diseases caused by bacteria from the Mycobacterium genus, excluding...
PR Newswire
11/09/2024

Teva to Present at the Bank of America 2024 Global Healthcare Conference

To access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the...
Nasdaq GlobeNewswire
11/09/2024

Annual Report 2023/24 - Strengthened commercial focus after challenging year

ANNOUNCEMENT NO. 273 11 September 2024Annual Report 2023/24 (1 July 2023 - 30 June 2024) Strengthened commercial focus after challenging year ChemoMetec's revenue fell by 8% in 2023/24 to DKK 407.4 million, and operating profit (EBITDA) was down by 26% to DKK 186.2 million. Revenue was adversely affected by a 35% decline in sales of instruments, while sales of consumables and services were up by 13% in total. During the year, ChemoMetec initiated a gradual launch of the XcytoMatic...
Nasdaq GlobeNewswire
11/09/2024

Guidance for the 2024/25 financial year

ANNOUNCEMENT NO. 272 11 September 2024 Guidance for the 2024/25 financial yearChemoMetec has today approved the annual report for 2023/24, including the guidance for 2024/25, which is considered inside information.For 2024/25, ChemoMetec expects revenue in the range of DKK 435-450 million (2023/24: DKK 407.4 million) and EBITDA in the range of DKK 216-223 (2023/24: DKK 186.2 million).The annual report for 2023/24, which is released along with this announcement, sets out the...
Nasdaq GlobeNewswire
11/09/2024

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of…

BOSTON and LONDON, Sept.11, 2024(GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a...
Nasdaq GlobeNewswire
11/09/2024

Global Health Exhibition Announces Opportunity for Healthcare Startups to secure…

Closely aligned with the Kingdom of Saudi Arabia's healthcare objectives including crisis response and health security, technological and digital transformation, public health and disease prevention and health innovation, Vision NextGen judges anticipate high demand to join a shortlist of 30 companies from an anticipated longlist of over 150 businesses. Six finalists drawn from the shortlist will present to the competition's expert judging panel live at the Exhibition on 23 October 2024. The…
PR Newswire
11/09/2024

Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial…

Oslo, September 11, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed with the investigators conducting the LUNGVAC trial (NCT05344209) to discontinue patient recruitment. LUNGVAC is an investigator-initiated, randomized Phase II trial designed to assess the impact of UV1 in combination with the checkpoint inhibitor cemiplimab or pembrolizumab as first-line...
Nasdaq GlobeNewswire
11/09/2024

Cell-Based Assays Market to Grow from USD 17.3B in 2024 to USD 24.3B by 2029 at…

Browse in-depth TOC on "Cell-Based Assays Market" Browse in-depth TOC on "Cell-Based Assays Market" 200 - Tables50 - Figures350 - Pages Market Segmentation by Offering The global cell-based assays market is categorized into consumables, instruments, software, and services. Among these, the services segment is projected to experience the highest CAGR during the forecast period. Increasingly, researchers and pharmaceutical companies are outsourcing aspects of their...
PR Newswire
11/09/2024

KFSHRC Announced a Strategic Partner for 2024 NYC C3 Summit Davos of Healthcare

RIYADH, Saudi Arabia, Sept.11, 2024(GLOBE NEWSWIRE) -- In a significant move to bolster its global presence, the King Faisal Specialist Hospital & Research Centre (KFSHRC) is set to join as a key partner in the 2024 NYC C3 Summit Davos of Healthcare, kicking off on Monday in New York City. Under the theme "Tech-Driven Healthcare Evolution & Breakthroughs: Addressing Future Global Challenges & Impact of Advanced Technologies," the summit will foster dialogue and...
Nasdaq GlobeNewswire
11/09/2024

RenovaroCube Announces Strategic Offering of Up to 20% Ownership

This opportunity will be available to all potential investors including current shareholders of RENB.Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology for multi-omics and multi-modal data analysis, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes, beginning with cancer.“Newly raised...
Nasdaq GlobeNewswire
11/09/2024

Tinnitus Quest Launches to Find a Cure for Hearing Disorder Affecting Millions

Despite the prevalence and profound impact of tinnitus, no cure or effective treatment is available. Many sufferers are simply advised to "learn to live with it." "Tinnitus Quest believes this status quo is unacceptable," said Sven Köllmann, founder of Tinnitus Quest. "We are committed to changing the narrative by funding agile research, investigating new research questions that have not been asked before, aimed at silencing tinnitus once and for all." Despite the…
PR Newswire
11/09/2024
Altri  Comunicati